Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Gains from Investment Securities (2019 - 2025)

Strata Critical Medical (SRTA) has disclosed Gains from Investment Securities for 7 consecutive years, with -$1.4 million as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities fell 162.49% to -$1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, up 1029.77% year-over-year, with the annual reading at -$4.3 million for FY2025, N/A changed from the prior year.
  • Gains from Investment Securities for Q4 2025 was -$1.4 million at Strata Critical Medical, down from -$33000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $14.9 million in Q2 2021, with the low at -$19.3 million in Q2 2022.
  • Average Gains from Investment Securities over 5 years is -$577666.7, with a median of -$55000.0 recorded in 2025.
  • The sharpest move saw Gains from Investment Securities crashed 11420.0% in 2023, then skyrocketed 2366.0% in 2024.
  • Over 5 years, Gains from Investment Securities stood at -$10.9 million in 2021, then soared by 129.72% to $3.2 million in 2022, then plummeted by 103.08% to -$100000.0 in 2023, then surged by 2366.0% to $2.3 million in 2024, then plummeted by 162.49% to -$1.4 million in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at -$1.4 million, -$33000.0, and -$77000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.